195 related articles for article (PubMed ID: 28577152)
1. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
[TBL] [Abstract][Full Text] [Related]
2. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
4. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
5. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
[TBL] [Abstract][Full Text] [Related]
8. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
9. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
10. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
11. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
Olsen J; Jensen KF; Olesen DS; Knoop A
J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
[TBL] [Abstract][Full Text] [Related]
12. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
[TBL] [Abstract][Full Text] [Related]
14. Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.
Heng JE; Raman S; Wong ZY; Beh VJN
Daru; 2024 Jun; 32(1):67-76. PubMed ID: 37903943
[TBL] [Abstract][Full Text] [Related]
15. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
[TBL] [Abstract][Full Text] [Related]
16. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
Waller CF; Möbius J; Fuentes-Alburo A
Br J Cancer; 2021 Apr; 124(8):1346-1352. PubMed ID: 33589773
[TBL] [Abstract][Full Text] [Related]
18. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
20. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
